Hematopoietic Cell Transplantation clinical trials at UC Davis
4 research studies open to eligible people
Engineered Donor Grafts (Orca-T) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
open to eligible people ages 18-75
This study will evaluate the safety, tolerability, and efficacy of an engineered donor graft ("Orca-T", a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells) in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies.
Sacramento, California and other locations
Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases
open to all eligible people
The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with Epstein-Barr virus (EBV) associated diseases.
Sacramento, California and other locations
Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease
open to eligible people ages 18-40
This is an open label, multicenter, Phase 1/2 study in approximately eight adults with severe Sickle Cell Disease (SCD). The study will evaluate the safety, tolerability, and efficacy of autologous hematopoietic stem cell transplantation using BIVV003.
Sacramento, California and other locations
Patients Who Have Participated in Children's Oncology Group Studies
open to all eligible people
This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.
Sacramento, California and other locations
Our lead scientists for Hematopoietic Cell Transplantation research studies include Mehrdad Abedi, MD Marcio H. Malogolowkin.
Last updated: